Hitisha Patel

Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models

Teeru Bihani, Hitisha Patel, Heike Arlt et al. · Clinical Cancer Research · 2017 · 160 citations

Medicine, Oncology, Pharmacology +14

Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors

Hitisha Patel, Nianjun Tao, Kyung-Min Lee et al. · Breast Cancer Research · 2019 · 78 citations · Full text

Medicine, Oncology, Pharmacology +17

Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer

Rui Xiong, Hitisha Patel, Lauren M. Gutgesell et al. · Journal of Medicinal Chemistry · 2015 · 61 citations · Full text

Medicine, Oncology, Pharmacology +15

Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor–Positive Breast Cancer Models with a Distinct Mechanism of Action

Ziyang Yu, Suqin He, Dannie Wang et al. · Clinical Cancer Research · 2017 · 33 citations

Medicine, Oncology, Pharmacology +17

A Chimeric SERM–Histone Deacetylase Inhibitor Approach to Breast Cancer Therapy

Hitisha Patel, Marton I. Siklos, Hazem Abdelkarim et al. · ChemMedChem · 2013 · 25 citations · Full text

Medicine, Oncology, Pharmacology +17